ALKS 8700

Drug Profile

ALKS 8700

Alternative Names: ALKS-8700

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alkermes plc
  • Class Fumarates; Small molecules
  • Mechanism of Action Immunomodulators; NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Multiple sclerosis

Most Recent Events

  • 27 Nov 2017 Alkermes signs a global license and collaboration agreement with Biogen for development and commercialisation of ALKS 8700 for Multiple sclerosis
  • 27 Oct 2017 Adverse events data from the phase III EVOLVE-MS-1 trial in Multiple sclerosis presented at the 7th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and the Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS-2017)
  • 16 Mar 2017 Alkermes initiates enrolment in the EVOLVE-2 phase III trial for Multiple Sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top